CN208243663U - A kind of Nano medication delayed release device as intravascular stent outsourcing - Google Patents
A kind of Nano medication delayed release device as intravascular stent outsourcing Download PDFInfo
- Publication number
- CN208243663U CN208243663U CN201721512717.XU CN201721512717U CN208243663U CN 208243663 U CN208243663 U CN 208243663U CN 201721512717 U CN201721512717 U CN 201721512717U CN 208243663 U CN208243663 U CN 208243663U
- Authority
- CN
- China
- Prior art keywords
- outsourcing
- intravascular stent
- drug
- delayed release
- tubular nanometer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 30
- 229940079593 drug Drugs 0.000 title claims abstract description 25
- 238000012946 outsourcing Methods 0.000 title claims abstract description 13
- 230000003111 delayed effect Effects 0.000 title claims abstract description 8
- 239000003292 glue Substances 0.000 claims 1
- 238000002513 implantation Methods 0.000 abstract description 9
- 238000000034 method Methods 0.000 abstract description 8
- 210000004204 blood vessel Anatomy 0.000 abstract description 5
- 230000006378 damage Effects 0.000 abstract description 5
- 230000028993 immune response Effects 0.000 abstract description 5
- 239000007943 implant Substances 0.000 abstract description 4
- 230000008569 process Effects 0.000 abstract description 4
- 239000003018 immunosuppressive agent Substances 0.000 abstract description 3
- 229940124589 immunosuppressive drug Drugs 0.000 abstract description 3
- 238000011065 in-situ storage Methods 0.000 abstract description 3
- 239000000463 material Substances 0.000 abstract description 3
- 239000000499 gel Substances 0.000 description 14
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000002184 metal Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 238000013146 percutaneous coronary intervention Methods 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 238000010146 3D printing Methods 0.000 description 1
- 206010007556 Cardiac failure acute Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 244000061408 Eugenia caryophyllata Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001194 anti-hemostatic effect Effects 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 206010007625 cardiogenic shock Diseases 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 229940126703 systemic medication Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Landscapes
- Materials For Medical Uses (AREA)
Abstract
The utility model relates to a kind of Nano medication delayed release devices as intravascular stent outsourcing, and including hollow tubular nanometer gel body, the tubular nanometer gel body is coated on intravascular stent, are embedded with drug in the nanogel.The outsourcing of flexible nano gel can effectively prevent damage of the bracket to endangium, enhance the physical compatibility and biocompatibility of bracket and blood vessel；By the release of the continuous in situ of implantation immunosuppressive drug nanogel and drug, may be implemented to inhibit stent implantation site immune response；In addition, tubular nanometer gel is made of the excellent material of elasticity, the implantation process of cooperation stenter to implant device (air bag) can be facilitated completely.
Description
Technical field
The utility model relates to treating cardiovascular disease field more particularly to a kind of nanometer medicines as intravascular stent outsourcing
Object delayed release device.
Background technique
To reach optimal prevention or therapeutic effect, need to give drug or bioactive substance to many diseases or state
And reach stable or lasting levels of drugs in vivo.To achieve the above object, prior art means using multiple dose administration or
Person is realized using the system of sustainable drug release or controllable drug release.Wherein, more meterings are also known as repeat administration and refer to by certain
The medication that administration reaches blood concentration and is maintained in therapeutic window is repeated several times in dosage, certain intervals time.Clinically
Often through multiple dose administration to maintain blood concentration in therapeutic window.Principle is that injection or medication are calculated according to blood concentration
Amount, the single drug duration is short, needs repeatedly to be administered patient.And controlled release pharmaceutical compositions have two big main advantages,
First is that higher treatment level can be maintained in longer time, second is that can subtract while reaching with quick releasing formulation same effect
Few medicining times, to improve the compliance of patient.Slow release method is efficiently used, drug is implanted directly into lesions position, when long
Between be sustained drug effect, can not only mitigate the pain of patient, also can the release of more scientific and reasonable control drug effect.Wherein, hydrogel conduct
Pharmaceutical carrier plays an important role in terms of medicine controlled releasing.The response performance of hydrogel be by the reversible volumetric phase transformation of gel come
Realize, and make it sensor, artificial muscle, drug controlled release, organizational project, catalyst system, enzyme in terms of
It has broad application prospects.
Currently, European and American developed countries have started the clinical application of similar technique many years ago.Such as chip implanted prosthetics, drug
It is big to be sustained side effect, silica gel stick technology is there are nondegradable defect, and patient must face the pain of second operation, and small plant
Enter in body technique, since release amount of medicine is uncontrollable, there is also huge side effects.And it is newest research shows that nanometer
Gel, which can be loaded, to be sent to inside cell and passes through biomembrane.This nanogel has good stability and can protect
Shield bioactie agent is not degraded by endocellular metabolism system.Nanogel conveys and improves oral and brain in systemic medication
Very big potential is shown in terms of the bioavilability of position.
Currently, cardiovascular disease relies primarily on drug therapy, patient's common practice is in related chronic diseases management process.And to medicine
Object control unstable undesirable Hemodynamics or cardiogenic shock, the arrhythmia cordis of threat to life/stop fight, myocardial infarction it is concurrent
The urgent skin percutaneous coronary intervention of the carry out such as disease, acute heart failure；To significant LM stenosis or it is related to narrow width proximal blood
Situations such as pipe lesion, carries out coronary bypass (bridging).
Currently, bracket (full name is blood vessel eyelid retractor) has become the main means of PCI treatment.Pass through the inability of bracket
Support maintains post-surgical vascular expansion state, while reducing injury repair influence, can narrow anti-hemostatic tube in a longer period of time.
Currently, the structure basis of most of brackets is bare metal stent (Bare Metal Stent, BMS).Metal (early stage
Based on stainless steel) ductility and supportive constitute maintain the physical expansion of bracket basis.But bare metal stent sheet
The histoincompatiblity of body results in the long-time stimulus to affected part, and it is flat to be especially surface-treated the problems such as inadequate destruction blood vessel
Slipped Clove Hitch structure.Inflammatory reaction stimulating endothelial cell simultaneously, leads to reangiostenosis and thrombus in stents, related post-operative recovery problem according to
Old protrusion.To solve this problem, bracket for eluting medicament (Drug-eluting Stent, DES) comes into being.Medicament elution branch
Frame is attached with the preferable coating of biological phasic property and slow releasing pharmaceutical using bare metal stent as structure basis on it, reduces to blood
Inhibit inner membrance fibroblast proliferation while tube wall stimulates.But it is existing, bracket is easy to be immunized in body in implant
System identification is foreign matter, generates strong immune response (absorption of such as immunoglobulin), cause bracket para-immunity reaction and
The formation of thrombus.
Utility model content
In view of the above-mentioned state of the art, the technical problem to be solved by the utility model is to provide a kind of conjunctions of structure
Reason, reduces the Nano medication delayed release device as intravascular stent outsourcing of immune response.
Technical solution adopted by the utility model to solve the above technical problems is as follows: a kind of receiving as intravascular stent outsourcing
Rice drug release device, including hollow tubular nanometer gel body, the tubular nanometer gel body is coated on intravascular stent
On.
Further, the outer diameter of the tubular nanometer gel body is 5mm.
Further, the internal diameter of tubular nanometer gel hollow chamber is 4mm.
It is the utility model compared with prior art that the utility model, which solves technical solution used by above-mentioned technical problem,
Beneficial effect be: the outsourcing of flexible nano gel can effectively prevent damage of the bracket to endangium, enhancing bracket with
The physical compatibility and biocompatibility of blood vessel；It is released by the continuous in situ of implantation immunosuppressive drug nanogel and drug
It puts, may be implemented to inhibit stent implantation site immune response；In addition, tubular nanometer gel is made of the excellent material of elasticity, it can
To facilitate the implantation process of cooperation stenter to implant device (air bag) completely.
Detailed description of the invention
Fig. 1 is novel overall structure diagram described in the utility model.
Specific embodiment
The following will be combined with the drawings in the embodiments of the present invention, to the skill embodiment in the utility model embodiment, and
The embodiment being not all of.Based on the embodiments of the present invention, those of ordinary skill in the art are not making creativeness
Every other embodiment obtained, fall within the protection scope of the utility model under the premise of labour.
As shown in Figure 1, a kind of Nano medication release device as intravascular stent outsourcing described in the utility model, including in
Empty tubular nanometer gel body, the tubular nanometer gel body are coated on intravascular stent.
Further, the outer diameter of the tubular nanometer gel body is 5mm.
Further, the internal diameter of tubular nanometer gel hollow chamber is 4mm.
Its preparation process can be laser processing or 3D printing.
It is the utility model compared with prior art that the utility model, which solves technical solution used by above-mentioned technical problem,
Beneficial effect be: the outsourcing of flexible nano gel can effectively prevent damage of the bracket to endangium, enhancing bracket with
The physical compatibility and biocompatibility of blood vessel；It is released by the continuous in situ of implantation immunosuppressive drug nanogel and drug
It puts, may be implemented to inhibit stent implantation site immune response；In addition, tubular nanometer gel is made of the excellent material of elasticity, it can
To facilitate the implantation process of cooperation stenter to implant device (air bag) completely.
It is obvious to a person skilled in the art that the present invention is not limited to the details of the above exemplary embodiments, and
And without departing substantially from the spirit or essential attributes of the utility model, it can realize that this is practical new in other specific forms
Type.Therefore, in all respects, the present embodiments are to be considered as illustrative and not restrictive, this is practical new
The range of type is indicated by the appended claims rather than the foregoing description, it is intended that containing for the equivalent requirements of the claims will be fallen in
All changes in justice and range are embraced therein.It should not treat any reference in the claims as limiting
Related claim.
Claims (3)
1. a kind of Nano medication delayed release device as intravascular stent outsourcing, which is characterized in that solidifying including hollow tubular nanometer
Glue ontology, the tubular nanometer gel body are coated on intravascular stent, are embedded with drug in the nanogel.
2. a kind of Nano medication delayed release device as intravascular stent outsourcing according to claim 1, which is characterized in that institute
The outer diameter for stating tubular nanometer gel body is 5mm.
3. a kind of Nano medication delayed release device as intravascular stent outsourcing according to claim 1, which is characterized in that institute
The internal diameter for stating tubular nanometer gel hollow chamber is 4mm.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201721512717.XU CN208243663U (en) | 2017-11-06 | 2017-11-06 | A kind of Nano medication delayed release device as intravascular stent outsourcing |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201721512717.XU CN208243663U (en) | 2017-11-06 | 2017-11-06 | A kind of Nano medication delayed release device as intravascular stent outsourcing |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN208243663U true CN208243663U (en) | 2018-12-18 |
Family
ID=64618886
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201721512717.XU Expired - Fee Related CN208243663U (en) | 2017-11-06 | 2017-11-06 | A kind of Nano medication delayed release device as intravascular stent outsourcing |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN208243663U (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116036387A (en) * | 2023-01-30 | 2023-05-02 | 博裕纤维科技（苏州）有限公司 | Preparation method of external-wrapping type drug-loaded visual nanofiber artificial vascular stent |
-
2017
- 2017-11-06 CN CN201721512717.XU patent/CN208243663U/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116036387A (en) * | 2023-01-30 | 2023-05-02 | 博裕纤维科技（苏州）有限公司 | Preparation method of external-wrapping type drug-loaded visual nanofiber artificial vascular stent |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6857214B2 (en) | Sustained release composition for injection and its use for treating joint inflammation and associated pain | |
| ES2300604T3 (en) | MEDICINAL DEVICE FOR THE SUPPLY OF MEDICINAL PRODUCT. | |
| US20190247306A1 (en) | Articles and methods of treating vascular conditions | |
| JP5153340B2 (en) | Drug release control composition and drug release medical device | |
| CN109152741A (en) | Biodelivery medium based on hydrogel | |
| CN105209086A (en) | Multi-layer biodegradable device having adjustable drug release profile | |
| MX2011000036A (en) | Octreotide implant having a release agent. | |
| CN107106506A (en) | The injectable particulate that super localization for therapeutic agent discharges | |
| CN108784895A (en) | A kind of expandable stent system | |
| CN208243663U (en) | A kind of Nano medication delayed release device as intravascular stent outsourcing | |
| CN101239216A (en) | Novel sacculus dilating catheter | |
| WO2017101022A1 (en) | Modified medical scaffold material | |
| CN104027793A (en) | Preparation method and application of nerve growth factor controlled-release nano-carrier | |
| CN207821956U (en) | A kind of expandable stent system | |
| CN102266595A (en) | Medicament coating titanium nail using chitosan gelatin as carrier | |
| CN103705910A (en) | Ziconotide injection hypodermic implant and preparation method thereof | |
| CN107137168B (en) | Degradable recoverable 4D prints the organic human body support of line style and its application method | |
| CN101677950A (en) | A method of promoting tissue repair | |
| Khankari et al. | A review on pulsatile drug delivery system | |
| CN208229126U (en) | A kind of storage unit of the Nano medication fixed convenient for implantation | |
| CN208611373U (en) | A kind of storage unit of the Nano medication convenient for operation | |
| CN106890368A (en) | For the ureter bracket and preparation method of tumour targeted therapy | |
| CN208003121U (en) | A kind of storage unit for stablizing sustained release Nano medication | |
| Masadeh et al. | Technical insight into biodegradable polymers used in implants | |
| CN103989685A (en) | Preparation method of compound lamotrigine subcutaneous implantable controlled-release glue rod |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20181218 |